Phase I Study of Zarnestra (R115777.USA30) and Gleevec (Imatinib Mesylate) in Chronic Phase Chronic Myelogenous Leukemia (CML).

Trial Profile

Phase I Study of Zarnestra (R115777.USA30) and Gleevec (Imatinib Mesylate) in Chronic Phase Chronic Myelogenous Leukemia (CML).

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2012

At a glance

  • Drugs Imatinib; Tipifarnib
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Dec 2009 Actual patient number (29) added as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top